---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-019194"
form_type: "8-K"
ticker: "AYTU"
cik: "0001385818"
company_name: "AYTU BIOPHARMA, INC"
filed_at: "2023-11-17T23:59:59+00:00"
generated_at: "2026-06-07T23:53:54.181846+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Aytu BioPharma signs 5-year manufacturing contract with Halo for two ADHD products

## Summary
- Entered Commercial Manufacturing Services Agreement with Halo Pharmaceutical for Adzenys XR ODT and Cotempla XR ODT.
- Initial term from Nov 13, 2023 to Nov 13, 2028; auto-renews for successive 3-year terms.
- Company must purchase 100% of its requirements for covered products from Halo, except for own manufacturing.
- Company supplies active ingredients; Halo handles manufacturing, QC, packaging, and validation.

## SEC filing metadata
- accession: 0001558370-23-019194
- form_type: 8-K
- ticker: AYTU
- cik: 0001385818
- company_name: AYTU BIOPHARMA, INC
- filed_at: 2023-11-17T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1385818/000155837023019194/0001558370-23-019194-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1385818/000155837023019194/aytu-20231113x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-019194
- JSON: https://secwatch.observer/filing/0001558370-23-019194.json
- Plain text: https://secwatch.observer/filing/0001558370-23-019194.txt

## Key facts
- Material Agreements
  AYTU BIOPHARMA, INC entered into Commercial Manufacturing Services Agreement with Halo Pharmaceutical, Inc. (effective 2023-11-13).
  - Action: entry
  - Agreement: supply
  - Counterparty: Halo Pharmaceutical, Inc.
  - Effective: 2023-11-13
  source text: On November 13, 2023, Aytu BioPharma, Inc. (the “ Company ”) entered into a Commercial Manufacturing Services Agreement (the “ Agreement ”), with Halo Pharmaceutical, Inc. (“ Halo ”), pursuant to which Halo will manufacture Adzenys XR ODT® and Cotempla XR ODT® products for the Company at Halo’s manufacturing facility.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1385818/000155837023019194/0001558370-23-019194-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.